Menu
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike
Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19
Financing to advance the scientific development of innovative COVID-19 nanobody treatments focused on protecting high-risk immunocompromised individuals
Company developing highly potent antibodies targeting the conserved S1 and S2 regions of SARS-CoV-2
Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022
Triple mode of action dengue fever program identified for development
Industry veteran with exceptional leadership experience to support
ExeVir’s new progressive pipeline against infectious diseases
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, announces publication in BioRxiv of a paper by VIB scientists showing, in in vivo mouse and hamster models, highly potent viral neutralizing activity, protection against infection by SARS-COV-2 and minimized development of alveolar [lung] damage, for XVR011, its unique Llama-derived VHH72-Fc antibody for potential treatment and prevention of Covid-19.
ExeVir, which is developing nanobody therapies providing broad protection against viral infections, including a lead candidate for coronaviruses, today announced that Michel Kazatchkine and Stef Heylen have been appointed to the Board. Both strengthen ExeVir’s Board by adding pertinent R&D, in depth infectious disease and significant global health experience as ExeVir moves from preclinical to clinical with its lead candidate XVR011.
